Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis

Recruiting in Palo Alto (17 mi)

+154 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Bristol-Myers Squibb

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of this study is to assess the safety and efficacy of oral deucravacitinib in participants with moderate to severe ulcerative colitis (UC).

Eligibility Criteria

Inclusion Criteria

You have been diagnosed with ulcerative colitis for at least 3 months before the screening.

You have ulcerative colitis that affects at least 15 centimeters of your colon, which will be confirmed by a colonoscopy or sigmoidoscopy before the start of the study.

You must have moderate to severe ulcerative colitis, which is a type of inflammatory bowel disease, as determined by certain symptoms and a diagnostic test.

Participant Groups

Group I: BMS-986165 Experimental Treatment 1 Intervention

Group II: Placebo Placebo Group 1 Intervention

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Consultants for Clinical Research Cincinnati, OH

Penn State Health Milton S. Hershey Medical Center Hershey, PA

The Vancouver Clinic Vancouver, WA

Rapid City Medical Center Rapid City, SD

More Trial Locations

Who Is Running the Clinical Trial?

Bristol-Myers Squibb Lead Sponsor

References